BOPA Questionnaire – Monitoring and Treatments for Immune-Related Myocarditis

The BOPA Immunotherapy Specialist Interest Group invites all BOPA members to complete this survey.
This builds on our previous work exploring the known disparity across the UK with regards to access to drugs for immune-related (IR) adverse effects. IR-myocarditis is a rare and serious complication of immune checkpoint inhibitors (ICI).

Firstly, we aim to understand what cardiac assessments are undertaken prior to ICI therapy and the monitoring during therapy. Also we are wanting to discover which drugs and in particular which steroid sparing agents are prescribed for IR-myocarditis. Please find below the link and a QR code to take you to the survey, which should take around 12 minutes to complete. Analysis of these results will be used to highlight the difficulties in treating patients with this life-threatening IR adverse effect.

https://forms.office.com/e/bURF4jkFNN

Please get in touch if you have any queries and thank you for your contribution.

Simon, Meera, Jo, Dharmisha and Alice

The BOPA Immunotherapy Specialist Interest Group

And the Research Subcommittee

Latest News

By Suriya Marshall on 14th March 2026

Parliamentary Intervention Sparks National Campaign to Protect NHS Staff from Hazardous Medicinal Products (HMPs)

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster London, 10 March 2026: Today, the Safer Healthcare and Biosafety Network (SHBN) launches…

Read article
By Suriya Marshall on 14th March 2026

Clinical Pharmacy Congress. 8th-9th May 2026

Dear BOPA member, We are excited to announce that we have partnered with Clinical Pharmacy Congress 2026. Clinical Pharmacy Congress is the UK’s leading event for clinical pharmacy professionals working across…

Read article
By BOPA Executive Committee on 13th March 2026

First UK Campaign to Protect Healthcare Workers from Exposure to Hazardous Medicinal Products (HMPs) launches in Westminster

London, 10 March 2026: The Safer Healthcare and Biosafety Network (SHBN) launches a new campaign titled “Protecting Healthcare Workers: Safer Handling of Hazardous Medicinal Products” to raise awareness of the dangers…

Read article
By BOPA on 13th March 2026

Invitation to Participate: SWEET-PLUS Study

You are invited to take part in a research study called SWEET-PLUS (NIHR Research for Patient Benefit: 207952), run by Newcastle and Oxford Brookes Universities. SWEET-PLUS aims to understand experiences…

Read article